Australian biotech sector tipped for strong growth

Small Caps03-19

Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420634122?lang=en_US&edition=fundamental","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/03/Australian-biotech-sector-growth-2024-ASX.jpg","is_english":true,"pubTime":"2024-03-19 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2420634122","market":"us","top_or_hot":-1,"title":"Australian biotech sector tipped for strong growth","media":"Small Caps","content":"<div>\n<p>Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it.\nInternational research firm KPMG recently forecast Australia could generate over $15 billion ...</p>\n\n<a href=\"https://smallcaps.com.au/australian-biotech-sector-tipped-strong-growth/\">Source Link</a>\n\n</div>\n","source":"smallcap_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Australian biotech sector tipped for strong growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAustralian biotech sector tipped for strong growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-19 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://smallcaps.com.au/australian-biotech-sector-tipped-strong-growth/><strong>Small Caps</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it.\nInternational research firm KPMG recently forecast Australia could generate over $15 billion ...</p>\n\n<a href=\"https://smallcaps.com.au/australian-biotech-sector-tipped-strong-growth/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://smallcaps.com.au/australian-biotech-sector-tipped-strong-growth/","article_id":"2420634122","we_media_id":null,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/03/Australian-biotech-sector-growth-2024-ASX.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420634122","pubTimestamp":1710815130,"sourceInfo":{"source_id":"smallcap_stock","name":"Small Caps"},"weMediaInfo":null,"summary":"Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it.International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration.Australia’s $1.2b biotech industry currently ranks fifth in the world in terms of research and translation.Meanwhile, IBIS World says the biotechnology market size in Australia has grown at a compound annual growth rate of 2.4% over the past five years.Melbourne-based Algorae Pharmaceuticals  recently reported strong progress with its data acquisition and customisation for artificial intelligence  biopharmaceutical prediction platform advances.Clinical-stage cell therapy company Chimeric Therapeutics  has achieved a number of recent successes in developing key clinical catalysts for 2024.Sydney-headquartered Radiopharm Theranostics  has obtained new data which identif","collect":0,"end_time":0,"defaultTopTitle":"smallcaps.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BK7508":"医药生物股","BK4185":"保健护理机构","PAA.AU":"PHARMAUST LTD","RAD.AU":"RADIOPHARM THERANOSTICS LTD","XAO.AU":"标普/澳交所 普通股指数","IMU.AU":"IMUGENE LTD","XJO.AU":"标普/澳交所 200指数","BK7007":"医疗保健设备","MPL.AU":"MEDIBANK PRIVATE LTD","THC":"泰尼特","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","XKO.AU":"标普/澳交所 300指数","BK7067":"生物科技","NTI.AU":"NEUROTECH INTERNATIONAL LTD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","CHM.AU":"CHIMERIC THERAPEUTICS LTD","BK7089":"人寿与健康保险","ODD":"ODDITY Tech Ltd.","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK7055":"建筑与工程","THC.AU":"Hydroponics Company","BK7501":"新冠治疗股","BK7096":"制药","MND.AU":"MONADELPHOUS GROUP LTD","1AI.AU":"ALGORAE PHARMACEUTICALS LTD"},"translate_title":"澳大利亚生物技术行业有望强劲增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1,"XJO.AU":1,"XAO.AU":1,"THC.AU":1,"THC":1,"RAD.AU":1,"PAA.AU":1,"ODD":1,"NTI.AU":1,"CHM.AU":1,"IMU.AU":1,"MPL.AU":1,"1AI.AU":1,"MND.AU":1},"content_text":"Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it.\nInternational research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration.\nAustralia’s $1.2b biotech industry currently ranks fifth in the world in terms of research and translation.\nMeanwhile, IBIS World says the biotechnology market size in Australia has grown at a compound annual growth rate of 2.4% over the past five years.\nASX biotech stocks making news\nA number of Australian biotech companies are attracting interest with major technology and disease treatment breakthroughs.\nThese include:\nAlgorae Pharmaceuticals\nMelbourne-based Algorae Pharmaceuticals (ASX: 1AI) recently reported strong progress with its data acquisition and customisation for artificial intelligence (AI) biopharmaceutical prediction platform advances.\nThe company said the first version of its AlgoraeOS AI platform is on schedule and anticipated by Q3 of 2024, with subsequent versions being progressively upgraded over a period of at least three years.\nPharmAust\nClinical-stage biotechnology company PharmAust (ASX: PAA) filed supplementary clinical data from its recently completed Phase 1 MEND study in support of its recent request for orphan drug designation (ODD) from the US Food and Drug Administration for its monepantel (MPL) treatment of motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS).\nThe company also recently announced positive top-line data from its Phase 1 MEND study involving 12 patients with MND/ALS.\nChimeric Therapeutics\nClinical-stage cell therapy company Chimeric Therapeutics (ASX: CHM) has achieved a number of recent successes in developing key clinical catalysts for 2024.\nThis has included receiving positive preliminary data for its CHM 1101 treatment for heavily pretreated glioblastoma patients, confirming advancement to next phase of CHM 1101 development.\nRadiopharm Theranostics\nSydney-headquartered Radiopharm Theranostics (ASX: RAD) has obtained new data which identifying a potential pathway for its innovative RAD 301 and 302 oncology developments.\nThe company is gaining in confidence that the RAD 301 / RAD 302 theranostic pair may eventually prove to be a promising approach to addressing the unmet medical needs of the world’s female population with tailored radiopharmaceuticals.\nNeurotech International\nNeurotech International (ASX: NTI) recently extended its Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients.\nNeurotech has secured Human Research Ethics Committee (HREC) clearance for the extension to 52 weeks of daily oral treatment with its NTI164 development.\nNTI164 is a proprietary drug formulation derived from a unique cannabis strain with low tetrahydrocannabinol (THC) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.\nImugene\nImugene’s (ASX: IMU) Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics has cleared its first cohort within the intratumoural monotherapy arm of the study.\nImugene is now ready to commence combination dosing solid tumour patients with CD19-targeting drug blinatumomab.\nKnown as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours and aims to evaluate the safety and efficacy of two routes of administration, intratumoural injection and intravenous infusion, either alone or in combination with blinatumomab.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420634122"}